Altre lingue Corvus Pharmaceuticals, Inc.

Azioni

CRVS

US2210151005

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 19/04/2024			Variaz. 5gg	Var. 1 gen.
1,4 ^USD	-0,71%		-8,50%	-20,45%

09/04	Corvus Pharmaceuticals, Inc. annuncia l'inizio dello studio clinico di Fase 1 controllato con placebo di soquelitinib per la dermatite atopica	CI
21/03	CORVUS PHARMACEUTICALS, INC. : Oppenheimer ancora positivo	ZM

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis	09/04
Corvus Pharmaceuticals, Inc. Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis	09/04
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results	20/03
Corvus Pharmaceuticals to Start Phase 1 Study of Atopic Dermatitis Treatment in Q2	19/03
Corvus: Q4 Earnings Snapshot	19/03
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results	19/03
Corvus Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	19/03
Corvus Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	19/03
Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2023 Financial Results on March 19, 2024	13/03
Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data at the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases	12/02
Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data At the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases	12/02
Sector Update: Health Care Stocks Mixed in Afternoon Trading	09/02
Sector Update: Health Care Stocks Mixed Pre-Bell Friday	09/02
Corvus Pharmaceuticals Says Soquelitinib Received FDA Orphan Drug Designation	09/02
Corvus Pharmaceuticals Shares Rise on Orphan Drug Designation	08/02
Corvus Pharmaceuticals Announces Orphan Drug Designation Granted to Soquelitinib for the Treatment of T Cell Lymphoma	08/02
Corvus Pharmaceuticals Appoints Jeffrey Arcara as Chief Business Officer	06/02
Corvus Pharmaceuticals, Inc. Appoints Jeffrey Arcara as Chief Business Officer	06/02
Corvus Pharmaceuticals Announces the Passing of Board Member Edith P. Mitchell	23/01
Corvus Pharmaceuticals Announces Demise of Edith P. Mitchell, Member of the Board of Directors	23/01

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Corvus Pharmaceuticals, Inc.

Azioni

CRVS

US2210151005

Altre lingue

Filtri